Blog
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
…
17th Dec 2025
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements
Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
…
17th Dec 2025
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade
Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
…
11th Feb 2025
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations
Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
…
8th Feb 2025
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy
What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
…
6th Feb 2025
Alsevalimab: Targeting CD47 for Cancer Research and Treatment
Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
…
6th Feb 2025
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements
Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
…
6th Feb 2025
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy
Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
…
6th Feb 2025
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research
Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
…
6th Feb 2025
Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research
Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re
…
6th Feb 2025
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy
Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
…
6th Feb 2025
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research
Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease
…
5th Feb 2025
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research
Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
…
4th Feb 2025
Talquetamab: Exploring its Role in Cancer Therapy and Ongoing Research
Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It
…
2nd Feb 2025
Naratuximab: Redefining Cancer Therapy with Precision Medicine
Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
…
1st Feb 2025
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research
Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
…
31st Jan 2025
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy
What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
…
31st Jan 2025
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting
Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
…
31st Jan 2025
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research
Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
…
29th Jan 2025
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights
Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
…
29th Jan 2025
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances
Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
…
29th Jan 2025
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research
Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
…
29th Jan 2025
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond
Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
…
29th Jan 2025
Adalimumab: Mechanism, Clinical Applications, and the Role of Biosimilars
Quick Facts About AdalimumabWhat is Adalimumab?Adalimumab is a fully human monoclonal antibody designed to neutralize tumor necrosis factor-alpha (TNF-α), a key cytokine involved in infl
…
29th Jan 2025